Abstract
Multiple myeloma (MM) differs from other lymphoid B malignancy by its characteristic bone disease. During the course of their MM, up to 80% of patients will suffer from this osteolytic disease or its sometimes-revealing complications. Assessment of MM-related bone disease is important: it can conduct to decide the initiation of antitumoral therapy. Conventional skeletal X-rays (but more and more often whole-body low-dose computed tomography (CT)) and spine and pelvis or preferential whole-body magnetic resonance imaging (MRI) are the gold-standard for the assessment at diagnosis and relapse. If necessary, CT is a complementary imaging method. The role of 18F-fluorodeoxyglucose positron emission tomography (PET)/CT increases in assessment of response to therapy and detection of MM minimal residual disease. Future will clarify the role of diffusion-weighted and dynamic contrast-enhanced MRI or of new imaging technologies such as PET/MRI.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
